Methods and compositions for treating chronic lung diseases

Abstract

The present invention provides, among other things, methods and compositions for treating Chronic Lung Disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1) or an agonist or an analog thereof.

1 . A method of treating Chronic Lung Disease comprising administering to a subject in need of treatment insulin-like growth factor-1 (IGF-1) or an agonist or an analog thereof. 
     
     
         2 . The method of  claim 1 , wherein the IGF-I or agonist or analog thereof comprises IGF-1 and an IGF binding protein. 
     
     
         3 . The method of  claim 2 , wherein the IGF-I or agonist or analog thereof comprises IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3). 
     
     
         4 . The method of any one of the preceding claims  claim 1 , wherein the subject in need of treatment is an infant. 
     
     
         5 - 6 . (canceled) 
     
     
         7 . The method of  claim 1 , wherein the IGF-I or agonist or analog thereof is administered subcutaneously, intravenously, intramuscularly, or orally. 
     
     
         8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein the IGF-I or agonist or analog thereof is administered at a dosage of about 100 to 500 micrograms/kg/24 hours. 
     
     
         10 - 11 . (canceled) 
     
     
         12 . The method of  claim 1 , wherein the IGF-I or agonist or analog thereof is administered from the time of birth up to post-menstrual age (PMA) of about 24-34 weeks. 
     
     
         13 . The method of  claim 1 , wherein the IGF-I or agonist or analog thereof is administered from the time of birth up to PMA of about 28 to 32 weeks. 
     
     
         14 . The method of  claim 1 , wherein the IGF-I or agonist or analog thereof is administered from the time of birth up to PMA of about 29 weeks plus 6 days. 
     
     
         15 . The method of  claim 1 , wherein the subject has reduced IGF-1 serum levels. 
     
     
         16 . The method of  claim 15 , wherein the reduced IGF-1 serum levels are about 30 to 50 micrograms/L. 
     
     
         17 . The method of  claim 1 , wherein the IGF -1 is recombinantly produced. 
     
     
         18 . The method of  claim 3 , wherein the IGFB P-3 is recombinantly produced. 
     
     
         19 . The method of  claim 3 , wherein the IGF-1 and the IGFBP-3 are complexed prior to administration to the subject. 
     
     
         20 . The method of  claim 3 , wherein the IGF-1 and IGFBP-3 are complexed in equimolar amounts. 
     
     
         21 . The method of  claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of Chronic Respiratory Morbidity (CRM) through 12 months corrected age (CA). 
     
     
         22 . The method of  claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of Bronchopulmonary dysplasia (BPD) through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months. 
     
     
         23 . The method of  claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of Severe Intraventricular Hemorrhage (IVH) Grade III or IV through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months. 
     
     
         24 . The method of  claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in reduced incidence of retinopathy of prematurity (ROP) through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months. 
     
     
         25 . The method of  claim 1 , wherein the administration of the IGF-I or agonist or analog thereof results in increased Functional Status as Assessed by PREMature Infant Index (PREMII) through postmenstrual age (PMA) 36 weeks, 40 weeks, 6 months, 8 months, 10 months, or 12 months.